SMITHKLINE BEECHAM TO FIGHT STH AFRICAN REFORMS

6 October 1996

SmithKline Beecham is to fight the moves by the government of South Africa to make generic prescribing mandatory in the country, and to limit the dispensing of medicines as part of its program to cut health care costs.

The company has filed a submission asking the Supreme Court's Transvaal Division to overturn South African Health Minister Nkosazana Zuma's proposal, R1150, which is part of a reform program to overhaul the country's health care system. A spokesperson for SmithKline Beecham in the UK told the Marketletter that the company is unable to make any comment while it is involved in litigation.

Ms Zuma also plans to allow only licensed persons, as yet undefined, to dispense medicines. The industry is afraid that the moves will deny doctors choice in prescribing and could force them to change established patient regimens, according to Reuters.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight